The Latest
-
Apple, OpenEvidence launch conversational health AI study and app
The tech juggernaut and clinical AI company will research what drives consumer trust and the quality of health AI responses, among other areas. Apple could use the findings to inform product development.
-
MiniMed gets FDA nod for tubeless insulin pump
MiniMed will go head to head with Tandem Diabetes Care as both companies debut their first tubeless pumps.
-
Tandem wins FDA clearance for tubeless automated insulin delivery system
The clearance tees up a 2027 launch of a product that analysts called Tandem’s “single most important commercial catalyst and growth driver.”
-
Olympus making strides on FDA quality concerns, CEO says
CEO Bob White said the endoscope manufacturer accelerated its remediation and quality improvement efforts to “provide the sustained evidence that the agency is expecting.”
-
FDA posts early alerts for 2 product removals
Intersurgical told customers to immediately stop using affected devices, while Arrow International instructed users to quarantine and return certain products.
-
Tandem recalls Mobi insulin pump, reports 230 adverse events
A problem with a false occlusion alarm could interrupt insulin delivery for users, according to an entry in the FDA’s recall database.
-
Bipartisan push possible to curb Trump tariffs
Three bills in Congress would significantly restrict presidential tariff power if they become law, and experts say there's appetite for change in trade policy.
-
Abbott’s defibrillation lead lands FDA approval and CE mark
The authorizations position Abbott to launch a purpose-built lead for left bundle branch area pacing in the U.S. and Europe.
-
J&J leads Francis Medical investment to fund prostate cancer device
With Johnson & Johnson’s support, Francis plans to take its water-vapor therapy device through the premarket approval process.
-
Oura makes bet on AI in healthcare with $625M Counsel Health buy
The planned acquisition comes as wearable firms push to up their healthcare offerings.
-
The image by Coolcaesar is licensed under CC BY-SA 4.0
Danaher’s Cepheid business to lay off 67 people in California
The job cuts at Danaher’s molecular diagnostics subsidiary will take place by the end of the year and affect mostly scientists and engineers, according to a state filing.
-
Virtuoso robot wins FDA nod for bladder tumor removal
Virtuoso Surgical’s robotic system can remove lesions in one piece in a minimally invasive procedure designed to improve cancer diagnosis and staging.
-
FDA seeks input on telesurgery, autonomous robotics
The agency is inviting public comment on a new discussion paper as it prepares to shape policy covering robotic medical devices with autonomous or remote teleoperation functions.
-
Getinge hires president of acute care therapies
Stacy Beske joins Getinge from Philips and will take over the role on Dec. 1.
-
Novocure denied FDA approval for metastatic cancer treatment
The FDA had uncertainty about the degree of clinical benefit for Novocure’s treatment of brain metastases, the company said.
-
Labcorp completes $375M Millennium Health takeover
The deal, which includes a $245 million upfront fee, expands the geographic reach of Labcorp’s drug testing business.
-
Natera promotes Solomon Moshkevich to CEO
The CEO change was unexpected and prompted a stock selloff Friday, analysts said, but the new chief executive is prepared for the role.
-
Top medtech conferences in 2027
From AdvaMed’s meeting in San Francisco to a robotics conference in Rome, next year’s calendar is already filled with medtech events to attend.
Updated Nov. 6, 2026 -
Siemens Healthineers to rebrand and separate its IVD business
The company is rebranding the unit as Olyrian Diagnostics and plans to set it up as a standalone business by mid-2028.
-
Tandem Diabetes Care names next CEO
Jeannette Bankes will take over the role from John Sheridan, who will retire at the end of the year after leading the company since 2019.
-
Medicare will cut billions from 340B, expand site-neutral payments in 2027
Regulators finalized a rule Wednesday that would slash payments for drugs in the controversial 340B program and equalize some payments between care sites. Hospitals railed against the rule.
-
Edwards bumps up sales forecast on TAVR strength in Q3
Going forward, the heart valve maker expects procedure volumes to rise following positive study data and expanded Medicare reimbursement.
-
3 takeaways from TCT 2026
Edwards’ TAVR results in moderate aortic stenosis drew applause from meeting attendees, while Medtronic’s renal denervation and Abbott’s left atrial appendage closure devices also produced positive study findings.
-
Boston Scientific, Blackstone agree to $455M deal to co-fund heart pump development
As part of the agreement, Blackstone may receive regulatory and commercial milestone payments, plus royalties on net sales.
-
MiniMed names David Segal chief medical officer
Segal is succeeding Robert Vigersky, who is transitioning to a chief medical officer emeritus role ahead of his planned retirement at the end of next year.